

1/

Government of Pakistan
Ministry of National Regulations and Services
Drug Regulatory Authority of Pakistan

Subject: Import Policy for Medicines.

DRAP's Policy Board in its 1st meeting approved Import Policy for finished drugs, as follows:

- (i). Product specific inspection of manufacturer abroad will be carried out before registration.
 - (ii). GMP inspection will be conducted at the time of renewal of registration.
2. Registration fee would be as follows: -
- (i). Anticancer, Immunosuppressant, HIV/AIDS, Biologicals including blood products, Contrast Media, new molecule, Medical Devices or any other drug not manufactured in Pakistan- Rs.50,000/- per product.
 - (ii). Imported Me-Too Products which are manufactured locally – Rs.200,000/- per product.
 - (iii). Renewal Fee same as above.
3. Drug Pricing Committee would fix Maximum Retail Price (MRP) for Anticancer, Immunosuppressant, HIV/AIDS, Biologicals including blood products, Contrast Media, New Chemical Entity or any other drug not manufactured in Pakistan. For Me-Too products, MRP would be fixed less than 20% of price fixed for locally manufactured drug / Molecule. These recommendations would be considered in Pricing Policy.
4. Inspection of all manufacturers be conducted except products approved by US-FDA, EMEA, or regulatory bodies of Japan and Australia, and products approved by World Health Organization.